Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment

• Published in: INTERNATIONAL JOURNAL OF OBESITY Vol. 47; no. 4; pp. 251 - 256
• Main Authors: Stenberg, Erik, Näslund, Erik
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2023; Nature Publishing Group
• Subjects: 692/699/2743/137/773; 692/699/2743/393; Adult; Agonists; Bariatric Surgery - adverse effects; Cardiovascular Diseases - etiology; Cohort analysis; Cohort Studies; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Epidemiology; Female; Gastrointestinal surgery; Generalized linear models; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor - agonists; Health Promotion and Disease Prevention; Humans; Hypoglycemic Agents - therapeutic use; Internal Medicine; Liraglutide; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Metabolism; Middle Aged; Obesity; Obesity - complications; Obesity - drug therapy; Obesity - epidemiology; Obesity, Morbid - complications; Patients; Public Health; Receptors; Statistical models; Surgery

Background Glucagon-like Peptide-1 receptor agonists (GLP-1 RA) and metabolic and bariatric surgery (MBS) both improve cardiovascular outcomes in patients with severe obesity and type-2 diabetes (T2D). The aim of the present study was to assess the impact of MBS on major cardiovascular adverse event...